the firm's post-grant practitioners are some of the most experienced in the country.


Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our


Get to know our History

Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our


A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.




From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +

Tokyo Office

Telephone: +81-3-6212-0550
Learn More +


Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

Stay informed with

Our Blogs

Enablement in a Post-Amgen World -- From Antibodies to Artificial Intelligence

Schedule :
Sponsor : Oblon IAM Lexology Webinar

Associated People

Oblon hosted a webinar with IAM entitled "Enablement in a Post-Amgen World -- From Antibodies to Artificial Intelligence," co-hosted by Sameer Gokhale and Richard Kelly on September 26, 2023 at 9:00am EDT.

In this webinar, we discussed how to avoid enablement issues in the U.S. in mechanical, chemical, and software technologies (such as AI) in view of the recent Supreme Court decision Amgen v. Sanofi.

In our common law system, there is no set of strict written rules governing what is required for enablement, as it is driven by the policy behind enablement and prior case law. The webinar explored the relevant case law and the policy behind enablement.

Patent practitioners need to understand how to address the issue of enablement. The webinar discussed how responses to an enablement challenge may include claim construction, expert testimony, and use of prior art amongst others.

We further examined how to avoid enablement issues including how to identify such issues during the drafting process and during prosecution. We looked at how the functional nature of software-related patents make them vulnerable to scrutiny after Amgen.